The store will not work correctly when cookies are disabled.
Menu
Account
Recombinant Proteins
Cytokines
Recombinant Human GM-CSF
Recombinant Human GM-CSF
Skip to the end of the images gallery
Skip to the beginning of the images gallery
Featured Products
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Background
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is secreted by several different types of cells, including activated T cells, B cells, macrophages, mast cells, endothelial cells, and fibroblasts, in response to cytokines or immune and inflammatory stimuli. It was originally described as a growth factor that can support in vitro colony formation of granulocyte-macrophage progenitor cells and has the function of stimulating the growth and differentiation of hematopoietic precursor cells from different lineages. GM-CSF has also been reported to have functional effects on non-hematopoietic cells and can induce human endothelial cell migration and proliferation. In addition, it stimulates the proliferation of a variety of tumor cell lines, including osteoblastic sarcoma, carcinoma, and adenocarcinoma cell lines. Human GM-CSF and mouse GM-CSF have 54% sequence identicality, but there is no biological effect between different species. GM-CSF is used as a drug to stimulate the production of white blood cells after chemotherapy and has recently been evaluated in clinical trials as a vaccine adjuvant in HIV-infected patients.
Reference
1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3.
2. 1989.N Engl J Med, 320: 253-4.
3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-10
4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27
5. Tran T, Fernandes DJ, Schuliga M, et al. 2005.BrJ Pharmacol, 145: 123-31.
The protein has a calculated MW of 14.5 kDa. The protein migrates as 25 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Appearance
Solution protein.
Stability & Storage
Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage.
12 months from date of receipt, -20 to -70 °C as supplied.
Concentration
0. 2 mg/mL
Formulation
Dissolved in sterile PBS buffer.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers.
Biological Activity
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The EC50 for this effect is 6-30 pg/mL.
Shipping Condition
Shipping with dry ice.
Handling
Centrifuge the vial prior to opening.
Usage
For Research Use Only! Not to be used in humans.
Quality Control
Purity: > 95 % by SDS-PAGE. Endotoxin: Less than 1.0 EU/µg as determined by LAL method.